2-(2-chlorobenzyl)pyrrolidine | 383127-80-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-chlorobenzyl)pyrrolidine
• 英文别名: 2-[(2-chlorophenyl)methyl]pyrrolidine
• CAS: 383127-80-8
• 化学式: C₁₁H₁₄ClN
• mdl: MFCD02663525
• 分子量: 195.692
• InChiKey: DPKCYWNTWVXNKT-UHFFFAOYSA-N

物化性质

• 沸点：
  280.1±15.0 °C(Predicted)
• 密度：
  1.118±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(2-chlorobenzyl)pyrrolidine 、 2-氨基-5-溴苯甲酸 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (2-Amino-5-bromo-phenyl)-[2-[(2-chlorophenyl)methyl]pyrrolidin-1-yl]methanone
  参考文献：
  名称：

  Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors

  摘要：

  Non-nucleoside inhibitors of HCV NS5b RNA polymerase were discovered by a fragment-based lead discovery approach, beginning with crystallographic fragment screening. The NS5b binding affinity and biochemical activity of fragment hits and inhibitors was determined by surface plasmon resonance (Biacore) and an enzyme inhibition assay, respectively. Crystallographic fragment screening hits with approximately 1-10mM binding affinity (K(D)) were iteratively optimized to give leads with approximately 200nM biochemical activity and low microM cellular activity in a Replicon assay.

  DOI：

  10.1016/j.bmcl.2008.03.056
• 作为产物：
  描述：

  、 邻氯氯苄 在 magnesium 、 lithium chloride 、 zinc(II) chloride 作用下， 以 四氢呋喃 为溶剂， 以71 %的产率得到2-(2-chlorobenzyl)pyrrolidine
  参考文献：
  名称：

  Alicyclic‐Amine‐Derived Imine‐BF₃ Complexes: Easy‐to‐Make Building Blocks for the Synthesis of Valuable α‐Functionalized Azacycles

  摘要：

  摘要 报告了一种通过相应的亚胺-BF3 复合物获得α-官能化脂环胺的新策略。可分离的亚胺-BF3 配合物在碱促进/18-冠-6 催化过程中通过 N-溴胺的脱氢卤化，然后加入三氟化硼醚化物而容易制备。有机锌和有机镁亲核物在常温下添加，无需低温条件。在原位制备亚胺-BF3 复合物的过程中，只需一次操作就能直接从母胺制备出 α-官能化吗啉和哌嗪。α-官能化吗啉还可以进一步制备，例如在 α′ 位上安装第二个取代基。

  DOI：

  10.1002/anie.202313247

文献信息

• [EN] NON-SYSTEMIC TGR5 AGONISTS<br/>[FR] AGONISTES DE TGR5 NON SYSTÉMIQUES
  申请人：ARDELYX INC

  公开号：WO2013096771A1

  公开（公告）日：2013-06-27

  Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.

  结构(I)的化合物，或其立体异构体、互变异构体、药学上可接受的盐或前药，其中R1、R2、R3、R4、R8、R9、R10、R11、R12、A1、A2、X、Y和Z如本文所定义。提供了这些化合物作为TGR5拮抗剂的用途，以及用于治疗各种适应症，包括II型糖尿病。
• NON-SYSTEMIC TGR5 AGONISTS
  申请人：Ardelyx, Inc.

  公开号：US20150148311A1

  公开（公告）日：2015-05-28

  Compounds having the following structure (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R 1 , R 2 , R 3 , R 4 , R 8 , R 9 , R 10 , R 11 , R 12 , A 1 , A 2 , X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.

  具有以下结构（I）或其立体异构体，互变异构体，药学上可接受的盐或前药的化合物，其中R1、R2、R3、R4、R8、R9、R10、R11、R12、A1、A2、X、Y和Z如本文所定义。本文还提供了这种化合物作为TGR5拮抗剂和治疗各种症状，包括II型糖尿病的用途。
• PYRIMIDINE DERIVATIVES
  申请人：Merck Patent GmbH

  公开号：US20180118721A1

  公开（公告）日：2018-05-03

  Compounds of Formula I or II in which R1, X1 and X2 have the meanings indicated in claim 1 , are MTH1 inhibitors and can be employed, inter alia, in the treatment of cancer.
• US6821964B2
  申请人：——

  公开号：US6821964B2

  公开（公告）日：2004-11-23
• Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors
  作者：Stephen S. Antonysamy、Brandon Aubol、Jeff Blaney、Michelle F. Browner、Anthony M. Giannetti、Seth F. Harris、Normand Hébert、Jörg Hendle、Stephanie Hopkins、Elizabeth Jefferson、Charles Kissinger、Vincent Leveque、David Marciano、Ethel McGee、Isabel Nájera、Brian Nolan、Masaki Tomimoto、Eduardo Torres、Tobi Wright

  DOI：10.1016/j.bmcl.2008.03.056

  日期：2008.5

  Non-nucleoside inhibitors of HCV NS5b RNA polymerase were discovered by a fragment-based lead discovery approach, beginning with crystallographic fragment screening. The NS5b binding affinity and biochemical activity of fragment hits and inhibitors was determined by surface plasmon resonance (Biacore) and an enzyme inhibition assay, respectively. Crystallographic fragment screening hits with approximately 1-10mM binding affinity (K(D)) were iteratively optimized to give leads with approximately 200nM biochemical activity and low microM cellular activity in a Replicon assay.